| Writing Group Member | Employment | Research Grant | Other Research Support | Speakers' Bureau/ Honoraria |
Expert Witness | Ownership Interest | Consultant/ Advisory Board |
Other |
|---|---|---|---|---|---|---|---|---|
| Raina M. Merchant | University of Pennsylvania | NIH (R01 PI not specific to cardiac arrest: “Digital Phenotyping and Cardiovascular Health”)* | None | None | None | None | None | None |
| Khalid Aziz | University of Alberta (Canada) | None | None | None | None | None | None | None |
| Katherine M. Berg | Beth Israel Deaconess Medical Center | NHLBI Grant K23 HL1288141 | None | None | None | None | None | None |
| Adam Cheng | Alberta Children's Hospital (Canada) | None | None | None | None | None | None | None |
| Eric J. Lavonas | Denver Health Emergency Medicine | BTG Pharmaceuticals (Denver Health (Dr Lavonas' employer) has research, call center, consulting, and teaching agreements with BTG Pharmaceuticals. BTG manufactures the digoxin antidote, DigiFab. Dr Lavonas does not receive bonus or incentive compensation, and these agreements involve an unrelated product. When these guidelines were developed, Dr Lavonas recused from discussions related to digoxin poisoning.)† | None | None | None | None | None | American Heart Association (Senior Science Editor)† |
| David J. Magid | University of Colorado | NIH†; NHLBI†; CMS†; AHA† | None | None | None | None | None | American Heart Association (Senior Science Editor)† |
| Ashish R. Panchal | The Ohio State University | None | None | None | None | None | None | None |
| Alexis A. Topjian | The Children's Hospital of Philadelphia, University of Pennsylvania | NIH* | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*Modest.
†Significant.